



These additions and changes are effective 4/12/25

Pharmacy Benefit Additions (these apply to Exchange only):

Cobenfy (xanomeline and trospium chloride) – Pharmacy benefit, Non-Preferred brand, PA

Livdelzi (seladelpar) – Pharmacy benefit, Non-Preferred brand, PA

Yorvipath (palopegteriparatide) – Pharmacy benefit, Non-Preferred brand, PA

Ebglyss (lebrikizumab-lbkz) – Pharmacy benefit, Preferred brand, PA

Nemlurio (nemolizumab-ilto) – Pharmacy benefit, Non-Preferred brand, PA and QL of 2 syringes per 28 days

Miplyffa (arimoclomol) – Pharmacy benefit, Non-Preferred brand, PA

Aqneursa (levacetylleucine) – Pharmacy benefit, Non-Preferred brand, PA

Itovebi (inavolisib) – Pharmacy benefit, Non-Preferred brand, PA

Revuforj (revumenib) – Pharmacy benefit, Non-Preferred brand, PA

Voranigo (vorasidenib) – Pharmacy benefit, Non-Preferred brand, PA

Liraglutide generic – Pharmacy benefit, Generic, PA

Zepbound (tirzepatide) - Pharmacy benefit, Non-Preferred brand, PA and QL of 4 pens per 28 days

Wezlana (Ustekinumab) – Pharmacy benefit, Preferred brand, PA

Pharmacy Benefit Changes (these apply to Exchange only):

OmvoH (mirikizumab-mrkz) – Pharmacy benefit, New indication, moderately to severely active Crohn's disease in adults

Cosentyx (secukinumab) – Pharmacy benefit, Criteria update and add QLs

Velsipity (etrasimod arginine) – Pharmacy benefit, Downtier, Criteria update

Zeposia (ozanimod) – Pharmacy benefit, Criteria update

Entyvio (vedolizumab) – Pharmacy benefit, Criteria update

Cibinqo (abrocitinib) – Pharmacy benefit, Criteria update

Rinvoq (upadacitinib) – Pharmacy benefit, Criteria update

Bimzelx (bimekizumab-bkzx) – Pharmacy benefit, New indication, Hidradenitis Suppurativa (HS)

Tremfya (guselkumab) – Pharmacy benefit, Downtier

Ofev (nintedanib) – Pharmacy benefit, Criteria update

Esbriet (pirfenidone) – Pharmacy benefit, Criteria update

Medical Benefit Additions/Changes (these apply to Medicare and Exchange):

Bizengri (zenocutuzumab-zbco) – Medical benefit, PA

Ziihera (zanidatamab) – Medical benefit, PA

Yesintek (ustekinumab-kfce) – Medical benefit, PA

Steqeyma (Ustekinumab-stba) – Medical benefit, PA

Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) – Medical benefit, PA, new formulation

bendamustine – Medical benefit, Criteria update